11月11日晚间,基因测序和人工智能医疗公司Tempus AI(TEM.O)股价出现大幅下跌,一度下跌6.08%至69.78美元,引发市场关注。主要原因是分析师机构Stifel当日将该股评级从"买入"下调至"持有",并将目标价从45美元上调至65美元。
Stifel表示,在Tempus AI公司评论2025年核心业务前景可能低于市场预期之后,该股估值水平看起来捉襟见肘。虽然该公司近期收购Ambry Genetics有望对整体业务产生积极影响,但Stifel预计Tempus AI的收入增长将放缓,尤其是数据部门,并指出Ambry在遗传性癌症检测市场的增长也有所放缓。
另一方面,虽然Tempus AI最新一季度营收同比大幅增长至1.81亿美元,但仍处于亏损状态,净亏损达7584万美元。高估值、业绩增长疲软等因素也可能令投资者对公司前景持谨慎态度。此外,美股主要指数当日小幅下滑,投资者风险偏好降低,也可能引发资金流出这类高估值科技股。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.